tiprankstipranks
Advertisement
Advertisement

HK:3681 Stock Latest News

SinoMab Starts Phase 2 Trial of IL‑25 Antibody SM17 in Chinese Atopic Dermatitis Patients
Company AnnouncementsSinoMab Starts Phase 2 Trial of IL‑25 Antibody SM17 in Chinese Atopic Dermatitis Patients
8d ago
3681
SinoMab Updates Board and Committee Structure to Clarify Governance Roles
PremiumCompany Announcements
SinoMab Updates Board and Committee Structure to Clarify Governance Roles
8d ago
3681
SinoMab BioScience Announces Resignations of Two Non-Executive Directors
PremiumCompany Announcements
SinoMab BioScience Announces Resignations of Two Non-Executive Directors
9d ago
3681
SinoMab Bioscience Sets Out Board and Committee Structure
PremiumCompany Announcements
SinoMab Bioscience Sets Out Board and Committee Structure
9d ago
3681
SinoMab Reports Positive Phase 1 Data for Subcutaneous SM17 in China
PremiumCompany Announcements
SinoMab Reports Positive Phase 1 Data for Subcutaneous SM17 in China
15d ago
3681
SinoMab Grants 11.6 Million Share Options to Key Employees
PremiumCompany AnnouncementsSinoMab Grants 11.6 Million Share Options to Key Employees
16d ago
3681
SinoMab Narrows Loss as Key Antibody Programs Advance and Funding Base Expands
Premium
Company Announcements
SinoMab Narrows Loss as Key Antibody Programs Advance and Funding Base Expands
16d ago
3681
SinoMab Ends Haikou Lease as It Shifts to Asset-Light Manufacturing Model
Premium
Company Announcements
SinoMab Ends Haikou Lease as It Shifts to Asset-Light Manufacturing Model
28d ago
3681
SinoMab BioScience Sets March Board Meeting to Approve 2025 Annual Results
PremiumCompany Announcements
SinoMab BioScience Sets March Board Meeting to Approve 2025 Annual Results
30d ago
3681
SinoMab’s New SM17 Trial Puts Atopic Dermatitis Back in Focus for HK:3681 Investors
PremiumCompany Announcements
SinoMab’s New SM17 Trial Puts Atopic Dermatitis Back in Focus for HK:3681 Investors
1M ago
3681
SinoMab Wins China IND Nod to Expand SM17 Into Inflammatory Bowel Disease
PremiumCompany Announcements
SinoMab Wins China IND Nod to Expand SM17 Into Inflammatory Bowel Disease
1M ago
3681
SinoMab’s SM17 IND Application for IBD Accepted by NMPA
PremiumCompany Announcements
SinoMab’s SM17 IND Application for IBD Accepted by NMPA
4M ago
3681
SinoMab Doses First Cohort with Subcutaneous SM17 in China Study
PremiumCompany AnnouncementsSinoMab Doses First Cohort with Subcutaneous SM17 in China Study
6M ago
3681
SinoMab BioScience Announces New Company Secretary Appointment
Premium
Company Announcements
SinoMab BioScience Announces New Company Secretary Appointment
6M ago
3681
SinoMab BioScience Reports Key Progress in Clinical Trials for 2025
Premium
Company Announcements
SinoMab BioScience Reports Key Progress in Clinical Trials for 2025
7M ago
3681
SinoMab Completes New Share Subscription to Raise HK$50.68 Million
PremiumCompany Announcements
SinoMab Completes New Share Subscription to Raise HK$50.68 Million
7M ago
3681
SinoMab BioScience Schedules Board Meeting to Review Interim Results
PremiumCompany Announcements
SinoMab BioScience Schedules Board Meeting to Review Interim Results
8M ago
3681
SinoMab Completes New Share Subscription to Boost Drug Development
PremiumCompany Announcements
SinoMab Completes New Share Subscription to Boost Drug Development
8M ago
3681
SinoMab BioScience Enters Strategic Biomedicine Partnership
PremiumCompany Announcements
SinoMab BioScience Enters Strategic Biomedicine Partnership
8M ago
3681
SinoMab BioScience Grants Over 46 Million Share Options to Employees and Service Providers
PremiumCompany AnnouncementsSinoMab BioScience Grants Over 46 Million Share Options to Employees and Service Providers
9M ago
3681
SinoMab Bioscience Announces New Share Subscription Agreement
Premium
Company Announcements
SinoMab Bioscience Announces New Share Subscription Agreement
9M ago
3681
SinoMab Withdraws BLA for Rheumatoid Arthritis Drug, Plans New Trials
Premium
Company Announcements
SinoMab Withdraws BLA for Rheumatoid Arthritis Drug, Plans New Trials
9M ago
3681

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >